An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
perjantai 27. huhtikuuta 2018 päivittänyt: Pfizer
A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
259
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Mannheim, Saksa, 68159
- Zentralinstitut fuer Seelische Gesundheit
-
-
-
-
-
Dnipropetrovsk, Ukraina, 49005
- Municipal Establishment "Dnipropetrovsk Regional Clinical Hospital n.a. Mechnikov"
-
Dnipropetrovsk, Ukraina, 49115
- Municipal Establishment "Dnipropetrovsk Regional Clinical Psychiatric Hospital"
-
Kyiv, Ukraina, 02660
- Kyiv City Psychoneurological Hospital #2
-
Kyiv, Ukraina, 04080
- Kyiv City Clinical Psychoneurological Hospital #1
-
Lugansk, Ukraina, 91045
- Lugansk Regional Clinical Psychoneurological Hospital
-
Poltava, Ukraina, 36006
- Poltava Regional Clinical Psychiatric Hospital n.a. O.F. Maltsev
-
Stepanivka, Kherson, Ukraina, 73488
- Kherson Regional Psychiatric Hospital, Department #3
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Yhdysvallat, 72201
- K & S Professional Research Services, LLC
-
-
California
-
Anaheim, California, Yhdysvallat, 92801
- Leisure Court Center
-
Escondido, California, Yhdysvallat, 92025
- Early Phase Investigational Center
-
Escondido, California, Yhdysvallat, 92025
- Synergy Clinical Research Center Of Escondido
-
Garden Grove, California, Yhdysvallat, 92845
- Collaborative Neuroscience Network, Inc.
-
Long Beach, California, Yhdysvallat, 90822
- Long Beach VA Healthcare System
-
Long Beach, California, Yhdysvallat, 90806
- Ocean View Psychiatric Health Facility
-
Orange, California, Yhdysvallat, 92868
- University of California Irvine Medical Center
-
Paramount, California, Yhdysvallat, 90723
- California Clinical Trials Medical Group
-
Paramount, California, Yhdysvallat, 90723
- LaPaz Geropsychiatric Center
-
San Diego, California, Yhdysvallat, 92123
- Sharp Mesa Vista Hospital
-
Santa Ana, California, Yhdysvallat, 92701
- Neuropsychiatric Research Center of Orange County
-
Torrance, California, Yhdysvallat, 90502
- Collaborative Neuroscience Network, Inc.
-
Torrance, California, Yhdysvallat, 90505
- Del Amo Hospital
-
-
District of Columbia
-
Washington, District of Columbia, Yhdysvallat, 20016
- Comprehensive Neuroscience, Incorporated
-
-
Florida
-
Bradenton, Florida, Yhdysvallat, 34208
- Florida Clinical Research Center, LLC
-
Maitland, Florida, Yhdysvallat, 32751
- Florida Clinical Research Center, LLC
-
Orlando, Florida, Yhdysvallat, 32810
- Lakeside Behavioral Healthcare
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30308
- Atlanta Center for Medical Research
-
-
Illinois
-
Hoffman Estates, Illinois, Yhdysvallat, 60169
- Alexian Brothers Center for Psychiatric Research
-
Hoffman Estates, Illinois, Yhdysvallat, 60169
- Alexian Brothers Behavioral Health Hospital
-
Hoffman Estates, Illinois, Yhdysvallat, 60169
- Chinmay K. Patel, D.O.
-
-
Louisiana
-
Lake Charles, Louisiana, Yhdysvallat, 70629
- Lake Charles Clinical Trials
-
Lake Charles, Louisiana, Yhdysvallat, 70601
- Lake Charles Memorial Hospital
-
-
Maryland
-
Rockville, Maryland, Yhdysvallat, 20850
- CBH Health, LLC
-
-
Missouri
-
Saint Louis, Missouri, Yhdysvallat, 63118
- St. Louis Clinical Trials, LC
-
-
New Jersey
-
Willingboro, New Jersey, Yhdysvallat, 08046
- CRI Worldwide, LLC
-
Willingboro, New Jersey, Yhdysvallat, 08046
- Lourdes Medical Center of Burlington County
-
-
New York
-
Hollis, New York, Yhdysvallat, 11423
- Comprehensive NeuroScience, Inc.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19139
- CRI Worldwide, LLC
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78754
- Community Clinical Research
-
Austin, Texas, Yhdysvallat, 78731
- FutureSearch Trials
-
Austin, Texas, Yhdysvallat, 78745
- TexasNeuroRehab Center
-
DeSoto, Texas, Yhdysvallat, 75115
- Insite clinical research
-
Houston, Texas, Yhdysvallat, 77007
- Bayou City Research, Ltd.
-
Houston, Texas, Yhdysvallat, 77081
- Behavioral Hospital - Bellaire
-
-
Washington
-
Kirkland, Washington, Yhdysvallat, 98033
- Eastside Therapeutic Resource
-
Kirkland, Washington, Yhdysvallat, 98034
- Fairfax Hospital
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta - 65 vuotta (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- Diagnosis of schizophrenia with acute exacerbation of illness
- The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation.
Exclusion Criteria:
- Subjects with evidence or history of clinically significant uncontrolled medical illness
- Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder.
- Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM-IV defined substance abuse within 3 months prior to screening.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Placebo Comparator: Plasebo
|
One tablet/capsule every 12 hours for 28 days
|
|
Kokeellinen: PF-02545920 5 mg
|
5 mg tablet every 12 hours for 28 days
15 mg tablet every 12 hours for 28 days
|
|
Kokeellinen: PF-02545920 15 mg
|
5 mg tablet every 12 hours for 28 days
15 mg tablet every 12 hours for 28 days
|
|
Active Comparator: Risperidone 3 mg
|
3 mg capsule every 12 hours for 28 days
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
Aikaikkuna: Baseline, Week 4
|
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia.
The scale consists of 30 items.
Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe).
The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210; higher score indicates greater severity.
|
Baseline, Week 4
|
|
Proportion of Participants With Dystonia Adverse Events
Aikaikkuna: Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
|
Participants were assessed for presence of symptoms for any one of the following: dystonia, oromandibular dystonia, and oculogyric crisis.
|
Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Positive, Negative, and General Subscales Score at Week 4
Aikaikkuna: Baseline, Week 4
|
PANSS - positive, negative, and general subscales assesses positive, negative and general psychopathological symptoms associated with schizophrenia respectively.
Seven (7) items each make up the positive scale (for example; delusions, conceptual disorganization, and hallucinatory behavior) and negative scale (for example; blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal) and 16 items make up the general scale (for example; somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, pre-occupation).
Each item is rated on a 7-point Likert scale from 1 (symptom not present) to 7 (symptoms extremely severe).
Total scores range for positive as well as negative subscale is 7 to 49 and for general subscale is 16 to 112; higher subscale score indicates greater severity.
|
Baseline, Week 4
|
|
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 4
Aikaikkuna: Baseline, Week 4
|
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state.
Clinician responded to a question "Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?" on the following scores: 1 (normal - not ill at all), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most severely ill participants).
Higher score = more affected.
|
Baseline, Week 4
|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Marder Factors Score at Week 4
Aikaikkuna: Baseline, Week 4
|
PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia.
The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology).
PANSS Marder positive symptoms subscale consists of 8 items with total score equal to sum of 8 items ranging from 8-56; Marder negative symptoms subscale and Marder disorganized thoughts (Dis.
Thought) subscale, each consists of 7 items with total score equal to sum of 7 items each, ranging from 7-49, Marder uncontrolled hostility/excitement (Uncon.
Hos/Exc) subscale and Marder anxiety/depression (Anx/Dep) subscale, each consists of 4 items with total score equal to sum of 4 items each ranging from 4-28.
Higher subscale score indicates greater severity.
|
Baseline, Week 4
|
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Derived Brief Psychiatric Rating Scale (BPRS) Core Score at Week 4
Aikaikkuna: Baseline, Week 4
|
PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia.
PANSS derived BPRS is an 18-item clinician rated scale which assesses symptoms such as hostility, suspiciousness, hallucinations, grandiosity, and a number of other psychiatric symptoms.
Items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom.
BPRS core score consists of 4 items (Conceptual disorganization, Hallucinatory behavior, Suspiciousness/persecution, Unusual thought content) with total score equal to sum of the 4 items, ranging from 4 to 28, with higher score indicating greater severity.
|
Baseline, Week 4
|
|
Clinical Global Impression - Improvement (CGI-I) Score
Aikaikkuna: Week 4
|
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse).
Clinician responded to a question: "Compared to your subject's condition at the beginning of treatment, how much has your subject changed?"
Compared to Baseline (Day 1), improvement was defined as score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.
Higher score = more affected.
|
Week 4
|
|
Change From Baseline in Global Assessment of Functioning (GAF) Score at Week 4
Aikaikkuna: Baseline, Week 4
|
GAF is a 100-point, clinician rated single item scale that rates the severity of illness-related impairment in psychological, social and occupational functioning of participants on a hypothetical continuum of mental illness to mental health.
The scale values range from 1 to 100 with lower score indicating greater severity of illness and is divided into 10 equal intervals (descriptors): from 1-10 (persistent danger of hurting self - serious suicidal acting with clear expectations of death) to 91-100 (superior functioning - no symptoms).
Each descriptor has a nine-point range to allow for some variability of severity within the descriptor.
|
Baseline, Week 4
|
|
Treatment Satisfaction Questionnaire for Medication (TSQM) Score
Aikaikkuna: Week 4
|
TSQM assesses the participant's level of satisfaction with study medication.
It consists of a 14-item questionnaire which comprises of 3 specific scales (effectiveness, side effects, convenience) and 1 global satisfaction scale.
Effectiveness, convenience and global satisfaction scale are rated on a 7-point scale (0= Extremely Dissatisfied, 1= Very Dissatisfied, 2= Dissatisfied, 3= Somewhat Satisfied, 4= Satisfied, 5= Very Satisfied, 6= Extremely Satisfied) and side effects are rated on a 5-point scale (0= Extremely Dissatisfied, 1=Very Dissatisfied, 2= Somewhat Dissatisfied, 3= Slightly Dissatisfied, 4= Not at all Dissatisfied).
Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.
|
Week 4
|
|
Change From Baseline in Body Weight at Week 4
Aikaikkuna: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Change From Baseline in Abdominal Girth at Week 4
Aikaikkuna: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Number of Participants With Clinically Significant Findings in Vital Signs and Electrocardiogram (ECG)
Aikaikkuna: Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
|
Clinically significant findings based on investigator's discretion were assessed in vital sign parameters (including pulse rate, blood pressure and body temperature) and ECG parameters (including respiratory rate, heart rate, PR interval, QRS interval, QT interval, QT corrected using Bazett's correction [QTcB] interval, and QT corrected using Fridericia's correction [QTcF]).
|
Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
|
|
Number of Participants With Clinically Significant Changes in Physical Examinations
Aikaikkuna: Screening, Week 4
|
Clinically significant findings in physical examinations based on investigator's discretion were assessed.
Screening was the 7 day time (from Day -8 to Day -2) before dosing on Day 1. Number of participants with clinically significant changes in physical examinations compared to screening was assessed.
|
Screening, Week 4
|
|
Number of Participants With Laboratory Test Abnormalities
Aikaikkuna: Screening up to end of study (7 to 10 days after administration of last dose of study medication)
|
Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(<) 0.8*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: <0.9*LLN,>1.1*upper
limit of normal (ULN); platelets: <0.5*LLN,>1.75*ULN,
white blood cell count: <0.6*LLN, >1.5*ULN; lymphocytes, total neutrophils: <0.8*LLN, >1.2*ULN; eosinophils, basophils, monocytes: >1.2*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: >1.1*ULN; liver function: bilirubin: >1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >3.0*ULN; protein, albumin: <0.8*LLN></0>1.2*ULN;
renal function:blood urea nitrogen,creatinine: >1.3*ULN; uric acid: >1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: <0.9*LLN,>1.1*ULN;
urinalysis: pH<4.5, >8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: <0.6*LLN,>1.5*ULN)
|
Screening up to end of study (7 to 10 days after administration of last dose of study medication)
|
|
Number of Participants With Abnormal White Blood Cell (WBC) Count and Absolute Neutrophil Count (ANC)
Aikaikkuna: Day 1 up to Week 4
|
Pre-defined criteria was established for WBC Count (less than 0.6 times the lower limit of normal) and absolute neutrophil count (less than 0.8 times the lower limit of normal) to define the values that would be identified as abnormal.
|
Day 1 up to Week 4
|
|
Number of Participants With Clinically Significant Laboratory Test Abnormalities for Fasting Insulin, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Cholesterol, Triglycerides, Hemoglobin Type A1c (HbA1c) and Prolactin
Aikaikkuna: Day 1 up to Week 4
|
Clinically significant findings based on investigator's discretion were assessed in laboratory parameters (including fasting insulin, high-density lipoprotein [HDL], low-density lipoprotein [LDL], Cholesterol, Triglycerides, glycosylated hemoglobin type A1c [HbA1c] and Prolactin).
|
Day 1 up to Week 4
|
|
Change From Baseline in Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parameter Scores at Week 4
Aikaikkuna: Baseline, Week 4
|
ESRS-A is a clinician rated scale consisting of 24 items to assess severity of extra-pyramidal symptoms for following parameters: parkinsonism (10 items), dystonia (6 items), dyskinesia (6 items) and akathisia (2 items).
Each item is scored on a 6-point Likert scale (0=absent, 1=minimal, 2=mild, 3=moderate, 4=severe, 5=extreme).
Total score for a parameter is average of individual item scores included under the parameter, ranging from 0 to 5, with higher score = more affected.
|
Baseline, Week 4
|
|
Change From Baseline in Movement Disorder Burden Score for Dystonia (MDBS-D) at Week 4
Aikaikkuna: Baseline, Week 4
|
MDBS-D score reflects the numbers and durations of movement disorder adverse events for dystonia, the severity of the events, required treatment, and the total number of days the participant received study treatment.
MDBS-D score = (S * D * C)/TTD; where S= Movement Disorder Severity Score for Dystonia (possible values: 1 [mild]; 2 [moderate]; 3 [severe]), D=adverse event duration (in days), C=concomitant medication factor (C=1.5 if an anti-cholinergic or beta blocker is used for the treatment of a movement disorder; C=1 if no concomitant medication is used), TTD=total treatment days for the participant.
Value for MDBS score may range from zero to infinity.
A higher MDBS-D score indicates a greater movement disorder adverse event liability compared to baseline.
|
Baseline, Week 4
|
|
Number of Participants With Response to Columbia-Suicide Severity Rating Scale (C-SSRS)
Aikaikkuna: Baseline, Week 1, 2, 3, 4, Follow-up (FU) (7 to 10 days after administration of last dose of study medication)
|
Data relevant to the assessment of suicidality is mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) event codes.
C-SSRS assesses whether participant experiences following: suicide attempt (Event code 2) (Response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (Event code 3) ("Yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), suicidal ideation (Event code 4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act/some intent to act without specific plan or with specific plan and intent), self-injurious behavior, no suicidal intent (Event code 7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").
Number of participants with "Yes" response for above mentioned categories are assessed.
Baseline is defined as the Week 0 measurement.
|
Baseline, Week 1, 2, 3, 4, Follow-up (FU) (7 to 10 days after administration of last dose of study medication)
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Perjantai 1. lokakuuta 2010
Ensisijainen valmistuminen (Todellinen)
Maanantai 1. elokuuta 2011
Opintojen valmistuminen (Todellinen)
Maanantai 1. elokuuta 2011
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 3. elokuuta 2010
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 3. elokuuta 2010
Ensimmäinen Lähetetty (Arvio)
Keskiviikko 4. elokuuta 2010
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 22. toukokuuta 2018
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Perjantai 27. huhtikuuta 2018
Viimeksi vahvistettu
Sunnuntai 1. huhtikuuta 2018
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Mielenterveyshäiriöt
- Skitsofreniaspektri ja muut psykoottiset häiriöt
- Skitsofrenia
- Huumeiden fysiologiset vaikutukset
- Neurotransmitterit
- Farmakologisen vaikutuksen molekyylimekanismit
- Keskushermostoa lamaavat aineet
- Antipsykoottiset aineet
- Rauhoittavat aineet
- Psykotrooppiset lääkkeet
- Serotoniinin aineet
- Dopamiini-aineet
- Serotoniiniantagonistit
- Dopamiiniantagonistit
- Risperidoni
Muut tutkimustunnusnumerot
- A8241012
- 2010-020764-38 (EudraCT-numero)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .